Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~7 days
Time for 50 % to be eliminated
Steady State
~30.2 days
≈ 4.3 half-lives
Accumulation
×2.0
Cmax at steady state ÷ Cmax first dose
Gone After
~49 days
after last dose
| Hour | % of peak |
|---|---|
| 0 | 100 |
| 117.6 | 61.6 |
| 225.4 | 118.4 |
| 336 | 175 |
| 450.8 | 109 |
| 558.6 | 149.7 |
| 672 | 193.7 |
| 784 | 122.1 |
| 891.8 | 159 |
| 1008 | 198.4 |
| 1117.2 | 126.5 |
| 1234.8 | 156.3 |
| 1352.4 | 96.2 |
| 1470 | 59.2 |
| 1587.6 | 36.5 |
| 1705.2 | 22.4 |
| 1822.8 | 13.8 |
| 1940.4 | 8.5 |
| 2058 | 5.2 |
| 2175.6 | 3.2 |
| 2293.2 | 2 |
Source: Novo Nordisk product monograph. Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. Semaglutide: ~7 days.
Semaglutide has a reported half-life of about 7 days. Under a weekly dosing schedule, steady state is reached at roughly 4.3 half-lives — about 30 days — and subsequent doses accumulate by a factor of about 2.0 over a single dose.
The blue line plots concentration as a percentage of the first-dose peak. The dashed reference line marks the steady-state peak. After the last dose, concentration drops below 1 % of the peak after about 49 days — seven half-lives.
Semaglutide is a GLP-1 mono-agonist studied at weekly doses of 0.25 to 2.4 mg for metabolic and weight-management indications. The 7-day half-life aligns precisely with a weekly dosing interval, producing the highest accumulation factor among the weekly GLP-1 class peptides modelled here.